The Possibilities of Mind-Altering Compounds | Dr. Suresh Muthukumaraswamy | The Tim Ferriss Show

The government department responsible for public health services in New Zealand, which conducts an annual survey on psychological distress.

An organization that began as a pilot immigration program in 2016 and has grown into a fellowship of over 500 technologists, creatives, investors, entrepreneurs, educators, and systems designers committed to using New Zealand as a base for global impact.

Multidisciplinary Association for Psychedelic Studies, whose trained therapists are available in New Zealand and could deliver MDMA-assisted therapy if approved.

A foundation that has funded joint programs focused on psychiatry, including the development of a certification program for psychedelic-assisted therapies in collaboration with institutions like Johns Hopkins, NYU, and Yale.

Services mentioned as providing crucial information about drug purity and dosing, which can help mitigate risks associated with illicitly obtained substances.

Pharmaceutical company that developed Spravato (esketamine nasal spray), the S-enantiomer of ketamine. While it allowed for patenting, its efficacy over generic ketamine is questioned.

A New Zealand company that has been researching slow-release formulations of ketamine, which is an area of interest for potentially modifying the drug's absorption and experience.

The process of obtaining payment for medical services, often requiring specific diagnostic codes from the DSM, which is relevant to the discussion of how psychedelic therapies might be covered.

A key aspect of open science where clinical trial protocols are published before the study begins, aiming to prevent data manipulation and ensure scientific rigor. Dr. Muthukumaraswamy's lab has adopted this practice.

A glutamate receptor heavily involved in neuroplasticity and long-term potentiation, which ketamine antagonizes. Its interaction with this receptor is a key focus in understanding ketamine's effects.

A non-invasive brain stimulation technique that may take about a month to show antidepressant effects, contrasting with the rapid onset of ketamine.

A therapeutic approach combining MDMA with psychotherapy, currently in Phase 3 clinical trials in the US for PTSD and considered a potential front-runner for wider adoption.

The S-enantiomer of ketamine, formulated as a nasal spray. marketed by Janssen, it is sold at a significantly higher price than generic ketamine, largely due to patent protection.

A classical psychedelic found in magic mushrooms, primarily acting on the serotonin 2A receptor. Research suggests it can have durable antidepressant effects, possibly linked to addressing root narratives.

Lysergic acid diethylamide, a classical psychedelic that works primarily through the serotonin 2A receptor. It is used in microdosing research and has been studied for its neuroimaging correlates.

A nasal spray containing esketamine, developed by Janssen. Although it allows for patenting, its efficacy compared to generic ketamine is debated, with a significant price difference.

A dissociative anesthetic and NMDA receptor antagonist used clinically for depression, known for its rapid onset of antidepressant effects compared to SSRIs. It has a complex pharmacology with multiple receptor interactions.

A muscarinic antagonist studied for potential rapid antidepressant effects. A study using an active placebo found no antidepressant response, suggesting the effects seen in previous research might be placebo-driven. It is also known for its effects on memory and amnesia.

Selective serotonin reuptake inhibitors, a class of conventional antidepressants that typically take 6-8 weeks to show effects, contrasting with the rapid action of ketamine.

Dimethyltryptamine, a classical psychedelic compound that, like LSD and psilocybin, is believed to primarily work through the serotonin 2A receptor.

A researcher from Johns Hopkins Medicine known for his extensive work with psilocybin, who suggests the durability of its antidepressant effects may be linked to addressing root narratives.

A researcher at Yale who has done significant work with ketamine, exploring its antidepressant effects.

Author of 'How to Change Your Mind,' which provides an overview of psychedelic indications, though some aspects, like the role of the default mode network, are debated.

A researcher in psychopharmacology who collaborated with Dr. Muthukumaraswamy on early psychedelic research, investigating the neuroimaging correlates of psilocybin and LSD.

Host of 'The Tim Ferriss Show' and an advocate for psychedelic research, who interviews Dr. Suresh Muthukumaraswamy on the possibilities of mind-altering compounds. He also promotes his 'Five Bullet Friday' newsletter.

A researcher based in Otago, New Zealand, who has conducted significant work with ketamine and its analogues, exploring its efficacy in anxiety and social anxiety disorders.

The scientist credited with synthesizing LSD, who famously experienced his first major trip while bicycling after absorbing the compound through his skin.

A professor and prominent researcher in psychopharmacology, who collaborated with Dr. Muthukumaraswamy on early research into the neuroimaging correlates of psilocybin and LSD.

Associate professor of psychopharmacology at the University of Auckland, researching the effects of various compounds, including psychedelics, on brain function and behavior, with a focus on mental health.

Mentioned as having created a significant fund ($15 million) specifically for breakthrough mental health therapeutics, highlighting a proactive approach that New Zealand currently lacks.

A US state being closely watched for its development of a regulatory framework for psilocybin-assisted therapies, expected to be established within the next 6-12 months.

Diagnostic and Statistical Manual of Mental Disorders, used for insurance reimbursement purposes and diagnosis coding. The speaker notes that many conditions listed in the DSM may share common underlying characteristics that psychedelics could potentially interrupt.